Previous 10 | Next 10 |
Central nervous system ((CNS)) disorder drug development is a particularly difficult branch of biopharma drug development. Intra-Cellular Therapies (ITCI) has experienced this firsthand, with inconsistent late-stage results for ITI-007 (Lumateperone), a promising therapy for certain CNS disord...
WALTHAM, Massachusetts , July 1, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that for the 11 th consecutive year, employees took a day out of the office to roll up their sleeves and volunteer with community organizations across the Greater Boston area a...
Alkermes (NASDAQ: ALKS ) isn’t shying away from tackling the complexity of central nervous system (CNS) disorders. CNS disorders include conditions such as schizophrenia, depression, addiction and multiple sclerosis, to name a few. Treating these conditions can often be difficu...
-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12...
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an...
SPDR Biotech ETF (NYSE: XBI ) provides investors diversified exposure to one of the most exciting industries in the market. Diversified is a relative term here because biotechnology companies, particularly those that are still in early stages of drug development, are often times the riskie...
Updated interim data from an ongoing single-arm, open-label Phase 3 clinical trial, EVOLVE-MS-1 , evaluating Biogen's (NASDAQ: BIIB ) diroximel fumarate (DF) in patients with relapsing multiple sclerosis (MS) showed a treatment effect and favorable safety profile. The data were present...
Diroximel fumarate significantly reduced disease activity in newly diagnosed relapsing multiple sclerosis (MS) patients and those previously treated with interferons or glatiramer acetate Data show treatment discontinuations due to gastrointestinal (GI) events occurred at a low rate o...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. No formal trade talks are scheduled between the U.S. and China, but President Trump...
News, Short Squeeze, Breakout and More Instantly...
Alkermes plc (ALKS) is expected to report $0.64 for Q2 2024 Acerinox ADR (ANIOY) is expected to report for Q2 2024 Allegion plc (ALLE) is expected to report $1.77 for Q2 2024 Deutsche Bank AG (DB) is expected to report $0.43 for Q2 2024 Pathward Financial Inc. (CASH) is expected t...
Alkermes plc Reports Second Quarter 2024 Financial Results PR Newswire — Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from C...
2024-07-22 10:45:03 ET Enbridge Inc (ENB) ENB is trading UP for the last 5 days, and it at trading at $36.59 with volume of 731,965 and a one day change of $0.05 (0.14%). Enbridge Inc has a 52-week low of 31.03 and a 52-week high of $38.36. The business's 50-day moving average price...